Sesen Bio (STU:PCBK) Other Long-Term Liabilities : €0.00 Mil (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio Other Long-Term Liabilities?

Sesen Bio's other long-term liabilities for the quarter that ended in Dec. 2022 was €0.00 Mil.

Sesen Bio's quarterly other long-term liabilities declined from Jun. 2022 (€1.70 Mil) to Sep. 2022 (€0.00 Mil) but then stayed the same from Sep. 2022 (€0.00 Mil) to Dec. 2022 (€0.00 Mil).

Sesen Bio's annual other long-term liabilities declined from Dec. 2020 (€82.18 Mil) to Dec. 2021 (€46.02 Mil) and declined from Dec. 2021 (€46.02 Mil) to Dec. 2022 (€0.00 Mil).

Sesen Bio Other Long-Term Liabilities Historical Data

The historical data trend for Sesen Bio's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Other Long-Term Liabilities Chart

Sesen Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Long-Term Liabilities

Get a 7-Day Free Trial

Sesen Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Sesen Bio Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Sesen Bio Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Sesen Bio's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sesen Bio (STU:PCBK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (STU:PCBK) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (STU:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor • 02-22-2010

Pacific Continental Corp. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-04-2009